<HTML>
<HEAD>
<TITLE>Filed by Bowne Pure Compliance</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">
<DIV style="font-size: 10pt">
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>

<P style="font-size: 14pt" align="center"><B>UNITED STATES<BR>
SECURITIES AND
EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P style="font-size: 18pt" align="center"><B>FORM 8-K</B>

<P style="font-size: 12pt" align="center"><B>CURRENT REPORT<BR>
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P style="font-size: 10pt" align="center"><B>Date of Report (Date of earliest
event reported): February 11, 2009</B>

<P style="font-size: 24pt" align="center"><B>TOMOTHERAPY
INCORPORATED<BR>
</B><FONT style="font-size: 10pt">(Exact name of registrant as
specified in its charter) </FONT>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="32%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="33%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="32%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>Wisconsin</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>001-33452</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>39-1914727</B></TD>
 </TR>
 <TR valign="top">
  <TD>(State or other Jurisdiction of Incorporation)</TD>
  <TD>&nbsp;</TD>
  <TD>(Commission File Number)</TD>
  <TD>&nbsp;</TD>
  <TD>(IRS Employer Identification No.)</TD>
 </TR>

</TABLE>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="49%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="49%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>1240 Deming Way<BR>
Madison,
Wisconsin<BR>
</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>53717</B></TD>
 </TR>
 <TR valign="top">
  <TD>(Address of Principal Executive Offices)</TD>
  <TD>&nbsp;</TD>
  <TD>(Zip Code)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="center">Registrant&#8217;s telephone number,
including area code: <B>(608) 824-2800</B>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="30%" border="0">

 <TR>
  <TD width="100%">&nbsp;</TD>
 </TR>
 <TR>
  <TD style="border-bottom: #000000 1px solid" nowrap><B>&nbsp;</B></TD>
 </TR>
 <TR>
  <TD nowrap>(Former name or former address if changed since last report.)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="left">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:

<P style="font-size: 10pt" align="left"><FONT face="Wingdings">o</FONT> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)<BR>
<BR>
<FONT face="Wingdings">o</FONT> Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<DIV
style="margin-top: 10pt; font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P style="font-size: 10pt" align="left"><B>Item&nbsp;2.02. Results of
Operations and Financial Condition.</B>

<P style="font-size: 10pt" align="left">On February&nbsp;11, 2009, TomoTherapy
Incorporated (the &#8220;Company&#8221;) issued a press release announcing its
financial results for the quarter ended December&nbsp;31, 2008.&nbsp; A copy of
the Company&#8217;s press release dated February&nbsp;11, 2009, titled
&#8220;TomoTherapy Reports Fourth Quarter Financial Results&#8221; is attached
hereto as Exhibit&nbsp;99.1.

<P style="font-size: 10pt" align="left">Exhibit&nbsp;99.1 contains
forward-looking statements within the meaning of the federal securities laws.
These statements are present expectations, and are subject to the limitations
listed therein and in the Company&#8217;s other reports filed with the
Securities and Exchange Commission, including that actual events or results may
differ materially from those in the forward-looking statements.

<P style="font-size: 10pt" align="left">The foregoing information (including
the exhibit hereto) is being furnished under &#8220;Item&nbsp;2.02 Results of
Operations and Financial Condition&#8221; (including the exhibit hereto) and
shall not be deemed &#8220;filed&#8221; for purposes of Section&nbsp;18 of the
Securities Exchange Act of 1934, as amended, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of 1933, as
amended, except as shall be expressly set forth by specific reference in such
filing.

<P style="font-size: 10pt" align="left"><B>Item&nbsp;9.01. Financial Statements
and Exhibits.</B>

<P style="font-size: 10pt; text-indent: 3%" align="left">(d)&nbsp;Exhibits.
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="6%">&nbsp;</TD>
  <TD width="3%">&nbsp;</TD>
  <TD width="91%">&nbsp;</TD>
 </TR>
 <TR style="font-size: 10pt" valign="bottom">
  <TD style="border-bottom: #000000 1px solid" nowrap
align="left"><B>Number</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid" nowrap
align="center"><B>Description</B></TD>
 </TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px; text-align: center">99.1 </DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Press Release dated February&nbsp;11, 2009,
titled &#8220;TomoTherapy Reports Fourth Quarter Financial Results&#8221;</TD>
 </TR>
<!-- End Table Body -->

</TABLE>
</DIV>&nbsp;

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P style="font-size: 10pt" align="center"><B>SIGNATURES</B>

<P style="font-size: 10pt; text-indent: 2%"
align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized. &nbsp;

<P style="font-size: 10pt; margin-left: 46%" align="left"><B>TOMOTHERAPY
INCORPORATED</B>

<P style="font-size: 10pt" align="left">Dated: February&nbsp;11, 2009

<P style="margin-top: -11pt; font-size: 10pt; margin-left: 46%"
align="center">By:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>/</B>s/
Stephen C.
Hathaway&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
<BR>
Stephen C. Hathaway <BR>
<I>Chief Financial Officer</I>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">3
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P style="font-size: 10pt" align="center"><B>EXHIBIT INDEX</B>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="6%">&nbsp;</TD>
  <TD width="3%">&nbsp;</TD>
  <TD width="91%">&nbsp;</TD>
 </TR>
 <TR style="font-size: 10pt" valign="bottom">
  <TD style="border-bottom: #000000 1px solid" nowrap
align="left"><B>Number</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid" nowrap
align="center"><B>Description</B></TD>
 </TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px; text-align: center">99.1 </DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Press Release dated February&nbsp;11, 2009,
titled &#8220;TomoTherapy Reports Fourth Quarter Financial Results&#8221;</TD>
 </TR>
<!-- End Table Body -->

</TABLE>
</DIV>&nbsp;

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">4
</DIV>
</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "c80389e8vk.htm", "description": "FORM 8-K", "secsgml_size_bytes": 9316}]
{"company-data": {"conformed-name": "TomoTherapy Inc", "cik": "0001317872", "assigned-sic": "3845", "irs-number": "000000000"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-33452", "film-number": "09589826"}, "business-address": {"street1": "1240 DEMING WAY", "city": "MADISON", "state": "WI", "zip": "53717-1954"}, "mail-address": {"street1": "1240 DEMING WAY", "city": "MADISON", "state": "WI", "zip": "53717-1954"}}
Filed by Bowne Pure Compliance
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported): February 11, 2009
TOMOTHERAPY
INCORPORATED
(Exact name of registrant as
specified in its charter)
Wisconsin
001-33452
39-1914727
(State or other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
1240 Deming Way
Madison,
Wisconsin
53717
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number,
including area code:
(608) 824-2800
(Former name or former address if changed since last report.)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of
Operations and Financial Condition.
On February 11, 2009, TomoTherapy
Incorporated (the "Company") issued a press release announcing its
financial results for the quarter ended December 31, 2008.  A copy of
the Company's press release dated February 11, 2009, titled
"TomoTherapy Reports Fourth Quarter Financial Results" is attached
hereto as Exhibit 99.1.
Exhibit 99.1 contains
forward-looking statements within the meaning of the federal securities laws.
These statements are present expectations, and are subject to the limitations
listed therein and in the Company's other reports filed with the
Securities and Exchange Commission, including that actual events or results may
differ materially from those in the forward-looking statements.
The foregoing information (including
the exhibit hereto) is being furnished under "Item 2.02 Results of
Operations and Financial Condition" (including the exhibit hereto) and
shall not be deemed "filed" for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of 1933, as
amended, except as shall be expressly set forth by specific reference in such
filing.
Item 9.01. Financial Statements
and Exhibits.
(d) Exhibits.
Number
Description
99.1
Press Release dated February 11, 2009,
titled "TomoTherapy Reports Fourth Quarter Financial Results"
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
TOMOTHERAPY
INCORPORATED
Dated: February 11, 2009
By:
/
s/
Stephen C.
Hathaway
Stephen C. Hathaway
Chief Financial Officer
EXHIBIT INDEX
Number
Description
99.1
Press Release dated February 11, 2009,
titled "TomoTherapy Reports Fourth Quarter Financial Results"